JP2023553532A5 - - Google Patents
Info
- Publication number
- JP2023553532A5 JP2023553532A5 JP2023560239A JP2023560239A JP2023553532A5 JP 2023553532 A5 JP2023553532 A5 JP 2023553532A5 JP 2023560239 A JP2023560239 A JP 2023560239A JP 2023560239 A JP2023560239 A JP 2023560239A JP 2023553532 A5 JP2023553532 A5 JP 2023553532A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- cancer
- composition according
- pharmaceutically acceptable
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063124665P | 2020-12-11 | 2020-12-11 | |
| US63/124,665 | 2020-12-11 | ||
| US202163214718P | 2021-06-24 | 2021-06-24 | |
| US63/214,718 | 2021-06-24 | ||
| US202163253012P | 2021-10-06 | 2021-10-06 | |
| US63/253,012 | 2021-10-06 | ||
| US202163277561P | 2021-11-09 | 2021-11-09 | |
| US63/277,561 | 2021-11-09 | ||
| PCT/US2021/062912 WO2022125962A1 (en) | 2020-12-11 | 2021-12-10 | Combination therapies for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023553532A JP2023553532A (ja) | 2023-12-21 |
| JP2023553532A5 true JP2023553532A5 (enExample) | 2024-12-17 |
Family
ID=81974006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560239A Pending JP2023553532A (ja) | 2020-12-11 | 2021-12-10 | 癌の処置のための併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240050441A1 (enExample) |
| EP (1) | EP4259147A4 (enExample) |
| JP (1) | JP2023553532A (enExample) |
| KR (1) | KR20230154793A (enExample) |
| AU (1) | AU2021396395A1 (enExample) |
| CA (1) | CA3201657A1 (enExample) |
| WO (1) | WO2022125962A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| CA3201612A1 (en) * | 2020-12-11 | 2022-06-16 | Leenus MARTIN | Combination therapies for the treatment of cancer |
| US20240293422A1 (en) * | 2021-06-24 | 2024-09-05 | Erasca, Inc. | Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer |
| WO2023059771A1 (en) * | 2021-10-06 | 2023-04-13 | Erasca, Inc. | Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors |
| WO2025226830A1 (en) * | 2024-04-23 | 2025-10-30 | Erasca, Inc. | Shp2 and egfr inhibitors for the treatment of chordoma |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100135780A (ko) * | 2008-03-06 | 2010-12-27 | 제넨테크, 인크. | Ｃ-ｍｅｔ 및 ｅｇｆｒ 길항제로의 조합 요법 |
| US8828391B2 (en) * | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| WO2014066606A2 (en) * | 2012-10-25 | 2014-05-01 | Glaxosmithkline Llc | Combination |
| US20140308274A1 (en) * | 2013-03-15 | 2014-10-16 | Mirna Therapeutics, Inc. | Combination cancer treatments utilizing synthetic oligonucleotides and egfr-tki inhibitors |
| CR20210175A (es) * | 2018-09-18 | 2021-06-01 | Nikang Therapeutics Inc | Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2 (shp2) |
| CA3133766A1 (en) * | 2019-03-29 | 2020-10-08 | Astrazeneca Ab | Osimertinib for use in the treatment of non-small cell lung cancer |
| CA3164995A1 (en) * | 2019-12-20 | 2021-06-24 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| US20210292330A1 (en) * | 2020-02-28 | 2021-09-23 | Erasca, Inc. | Pyrrolidine-fused heterocycles |
-
2021
- 2021-12-10 JP JP2023560239A patent/JP2023553532A/ja active Pending
- 2021-12-10 KR KR1020237023446A patent/KR20230154793A/ko not_active Abandoned
- 2021-12-10 CA CA3201657A patent/CA3201657A1/en active Pending
- 2021-12-10 WO PCT/US2021/062912 patent/WO2022125962A1/en not_active Ceased
- 2021-12-10 EP EP21904509.3A patent/EP4259147A4/en not_active Withdrawn
- 2021-12-10 US US18/256,089 patent/US20240050441A1/en active Pending
- 2021-12-10 AU AU2021396395A patent/AU2021396395A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023553532A5 (enExample) | ||
| JP7572958B2 (ja) | Ｔｎｏ１５５及びｋｒａｓｇ１２ｃ阻害剤を含む医薬組合せ | |
| CN101678029B (zh) | 基于嘌呤的cdk抑制剂与酪氨酸激酶抑制剂的组合及其在治疗增生性疾病中的用途 | |
| JP2024023295A (ja) | Ｓｈｐ２の活性を阻害するための化合物の製造方法 | |
| JP2022511351A5 (enExample) | ||
| CN111527103A (zh) | 用于治疗或预防her驱动的抗药性癌症的化合物、组合物和方法 | |
| WO2023140329A1 (ja) | がんの治療または予防用医薬 | |
| JP2022519385A (ja) | Ｔｎｏ１５５及びｐｄ－１阻害剤を含む医薬組合せ | |
| KR20240021237A (ko) | 두경부암 치료를 위한 egfr 저해제 | |
| CN103402519B (zh) | 肿瘤治疗剂 | |
| JP2021510376A5 (enExample) | ||
| JP2020528907A5 (enExample) | ||
| BR112020001695A2 (pt) | compostos macrocíclicos e usos dos mesmos | |
| JP2019533670A5 (enExample) | ||
| JP2022545005A5 (enExample) | ||
| JP2017537114A5 (enExample) | ||
| JP2021536507A (ja) | Ｈｅｒ駆動性がんを治療または予防するための化合物、組成物、及び方法 | |
| WO2013100014A1 (ja) | 抗腫瘍剤の効果増強剤 | |
| CN1674905A (zh) | 在癌症治疗中zd6474、血管内皮生长因子抑制剂和放射疗法的组合 | |
| JP2024520630A5 (enExample) | ||
| JP2020114849A (ja) | Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用 | |
| JP2023532675A5 (enExample) | ||
| JP2023553534A5 (enExample) | ||
| JP2024125139A5 (enExample) | ||
| JP2022519532A5 (enExample) |